Brief: 2Seventy Bio - Abecma (Idecabtagene Vicleucel, Or Ide-Cel) Generated About $77 Million In U.S. Revenue During Q3 2024
31/10/2024 11:17
Oct 31 (Reuters) - 2Seventy Bio Inc TSVT.O :
* 2SEVENTY BIO - ABECMA (IDECABTAGENE VICLEUCEL, OR IDE-CEL)
GENERATED ABOUT $77 MILLION IN U.S. REVENUE DURING Q3 2024
* 2SEVENTY BIO- CO, BRISTOL MYERS SQUIBB SHARE EQUALLY IN
ALL
PROFITS, LOSSES RELATED TO DEVELOPMENT, MANUFACTURE,
COMMERCIALIZATION OF ABECMA IN U.S
Source text: ID:n0001860782-24-000106
Further company coverage: TSVT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 2Seventy Bio
See all news2Seventy Bio Inc expected to post a loss of 17 cents a share - Earnings Preview
2Seventy Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: 2Seventy Bio Q4 Basic EPS USD -0.37
2Seventy Bio Inc expected to post a loss of 26 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney